Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age 18 and above able to provide informed consent to participate~* Subject with stable ocular health, defined as no ocular conditions requiring ongoing topical therapy or recent surgical intervention~Exclusion Criteria:~* Adults unable to consent~* Individuals less than 18 years of age~* Prisoners~* Pregnant women.~* Known contradictions or sensitivities to study medication (oxymetazoline)~* Ocular surgery within the past 3 months or refractive surgery within the past six months~* Grossly abnormal lid margins, anatomical abnormalities, previous eyelid or orbital surgery~* Variable ptosis or eyelid position (e.g., myasthenia gravis, thyroid eye disease, or blepharospasm)~* Any ocular or systemic condition that, in the opinion of the investigator, would confound study data, interfere with the subject's study participation, or affected the subject's safety or trial parameters~* Presence of an active ocular infection~* Prior (within 5 days of beginning study treatment) use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines (including over the counter and herbal topical ophthalmic medications), phenylephrine dilating drops, any other topical ophthalmic agents~* Inability to sit comfortably for 15 - 30 minutes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Upneeq Group (Type: EXPERIMENTAL): Participants in this group will receive a one-time dosing of oxymetazoline hydrochloride 0.1% (1 drop applied to ocular surface of each eye of patients in the treatment group)
- Control Group (Type: SHAM_COMPARATOR): Participants in this group will receive a one-time dosing of balanced saline solution (1 drop applied to ocular surface of each eye of patients in the control group)

Based on this trial design, predict the completion outcome and termination type (if applicable).